<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03232073</url>
  </required_header>
  <id_info>
    <org_study_id>AC-058B303</org_study_id>
    <nct_id>NCT03232073</nct_id>
  </id_info>
  <brief_title>Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis</brief_title>
  <acronym>OPTIMUM-LT</acronym>
  <official_title>Multicenter, Non-comparative Extension to Study AC-058B301, to Investigate the Long-term Safety, Tolerability, and Control of Disease of Ponesimod 20 mg in Subjects With Relapsing Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study AC-058B301 (OPTIMUM; NCT02425644) has been designed to investigate the efficacy,
      safety and tolerability of ponesimod in subjects with relapsing multiple sclerosis (RMS). The
      AC-058B303 study is the long-term extension for the core study AC-058B301. The purpose of
      this long term extension of the core study AC-058B301 is to characterize the long-term
      safety, tolerability, and control of disease of ponesimod 20 mg in subjects with RMS.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 17, 2017</start_date>
  <completion_date type="Anticipated">April 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a single-group open-label extension study to investigate long-term safety, tolerability and control of disease of ponesimod 20 mg in subjects with RMS. Statistical analyses will be descriptive and therefore all endpoints are exploratory in nature. All exploratory endpoints are listed under primary outcomes.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized confirmed relapse rate (ARR)</measure>
    <time_frame>Analysis period: From day 1 in core study (Enrollment) to end-of-treatment (EOT) in the extension study, i.e. for up to 354 weeks</time_frame>
    <description>defined as the number of confirmed relapses per subject-year</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time from core study randomization to first confirmed relapse</measure>
    <time_frame>Analysis period: From day 1 in core study (Enrollment) to end-of-treatment (EOT) in the extension study, i.e. for up to 354 weeks</time_frame>
    <description>Time from enrollment in core study to first confirmed relapse</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to first 12-week confirmed disability accumulation (CDA)</measure>
    <time_frame>Analysis period: From day 1 in core study (Enrollment) to end-of-treatment (EOT) in the extension study, i.e. for up to 354 weeks</time_frame>
    <description>Time from core baseline to first 12-week CDA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to first 24-week confirmed disability accumulation (CDA)</measure>
    <time_frame>Analysis period: From day 1 in core study (Enrollment) to end-of-treatment (EOT) in the extension study, i.e. for up to 354 weeks</time_frame>
    <description>Time from core baseline to first 24-week CDA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patients with absence of relapses</measure>
    <time_frame>Analysis period: From day 1 in core study (Enrollment) to end-of-treatment (EOT) in the extension study, i.e. for up to 354 weeks</time_frame>
    <description>Number of patients with absence of relapses during study period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>Analysis period: From day 1 in core study (Enrollment) to end-of-treatment (EOT) in the extension study, i.e. for up to 354 weeks</time_frame>
    <description>Change from baseline in EDSS at all assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of no evidence of disease activity (NEDA) status at week 108 and end-of treatment (EOT) according to NEDA 3</measure>
    <time_frame>Analysis period: From day 1 in core study (Enrollment) to end-of-treatment (EOT) in the extension study, i.e. for up to 354 weeks</time_frame>
    <description>NEDA 3 defined by the absence of confirmed relapse, GD+ T1 lesions, new or enlarging T2 lesions and 12-week CDA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of no evidence of disease activity (NEDA) status at week 108 and end-of treatment (EOT) according to NEDA 4</measure>
    <time_frame>Analysis period: From day 1 in core study (Enrollment) to end-of-treatment (EOT) in the extension study, i.e. for up to 354 weeks</time_frame>
    <description>NEDA 4 defined by the absence of confirmed relapse, GD+ T1 lesions, new or enlarging T2 lesions and 12-week CDA, and annual brain volume change â‰¥ -0.4% from baseline to all assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change from baseline in brain volume (PCBV) measured by magnetic resonance imaging (MRI)</measure>
    <time_frame>Analysis period: From day 1 in core study (Enrollment) to end-of-treatment (EOT) in the extension study, i.e. for up to 354 weeks</time_frame>
    <description>Change from baseline in brain volume at all assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative number of combined unique active lesions (CUAL) measured by MRI</measure>
    <time_frame>Analysis period: From day 1 in core study (Enrollment) to end-of-treatment (EOT) in the extension study, i.e. for up to 354 weeks</time_frame>
    <description>Cumulative number of combined unique active lesions (CUAL) defined as new Gd+ T1 lesions plus new or enlarging T2 lesions (without double-counting the lesions) at all assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of number of Gd+ T1 lesions by MRI</measure>
    <time_frame>Analysis period: From day 1 in core study (Enrollment) to end-of-treatment (EOT) in the extension study, i.e. for up to 354 weeks</time_frame>
    <description>Number of Gd+ T1 lesions at all assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative number of new or enlarging T2 lesions measured by MRI</measure>
    <time_frame>Analysis period: From day 1 in core study (Enrollment) to end-of-treatment (EOT) in the extension study, i.e. for up to 354 weeks</time_frame>
    <description>Cumulative number of new or enlarging T2 lesions (relative to baseline) at all assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of volume of brain lesions measured by MRI</measure>
    <time_frame>Analysis period: From day 1 in core study (Enrollment) to end-of-treatment (EOT) in the extension study, i.e. for up to 354 weeks</time_frame>
    <description>Determination of MRI lesions (T2 lesions, T1 hypointense lesions) at all assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absence of MRI lesions</measure>
    <time_frame>Analysis period: From day 1 in core study (Enrollment) to end-of-treatment (EOT) in the extension study, i.e. for up to 354 weeks</time_frame>
    <description>Absence of MRI lesions (Gd+ T1 lesions, new or enlarging T2 lesions) at all assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of proportion of Gd+ lesions at baseline evolving to persistent black holes (PBHs)</measure>
    <time_frame>Analysis period: From day 1 in core study (Enrollment) to end-of-treatment (EOT) in the extension study, i.e. for up to 354 weeks</time_frame>
    <description>Proportion of Gd+ lesions at baseline evolving to PBHs at all assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimation of incidence rates of adverse events (AEs)</measure>
    <time_frame>Analysis period: From day 1 in core study (Enrollment) to end-of-treatment (EOT) in the extension study, i.e. for up to 354 weeks</time_frame>
    <description>Incidence rates of treatment-emergent AEs, severe AEs, AEs of special interest and AEs leading to premature discontinuation of study treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimation of incidence rates of treatment-emergent morphological ECG abnormalities</measure>
    <time_frame>Analysis period: From day 1 in core study (Enrollment) to end-of-treatment (EOT) in the extension study, i.e. for up to 354 weeks</time_frame>
    <description>ECG abnormalities as defined by the ECG provider</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of cardiac rhythms measured by electrocardiogram (ECG) parameters</measure>
    <time_frame>Analysis period: From day 1 in core study (Enrollment) to end-of-treatment (EOT) in the extension study, i.e. for up to 354 weeks</time_frame>
    <description>Absolute values by visit for 12-lead ECG parameters (HR, PR, QRS, QT, QTcB, QTcF)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline values by visit for cardiac rhythms</measure>
    <time_frame>Analysis period: From day 1 in core study (Enrollment) to end-of-treatment (EOT) in the extension study, i.e. for up to 354 weeks</time_frame>
    <description>Change from baseline values by visit for ECG parameters (HR, PR, QRS, QT, QTcB, QTcF)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ECG parameters from pre-dose to selected post-dose assessments</measure>
    <time_frame>Analysis period: From day 1 in extension study to end-of-treatment (EOT) in extension study, i.e. for up to 240 weeks</time_frame>
    <description>Change in ECG parameters (HR, PR, QRS, QT, QTcB, QTcF) from pre-dose to selected post-dose assessments (1h, 2h, 3h, 4h) on day 1 of extension study and on day of re-initiation of study treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute values and percent change from baseline in forced expiratory volume and forced vital capacity</measure>
    <time_frame>Analysis period: From day 1 in core study (Enrollment) to end-of-treatment (EOT) in the extension study, i.e. for up to 354 weeks</time_frame>
    <description>Absolute values and percent change from baseline in forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) at all assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of treatment-emergent decrease from baseline in forced expiratory volume and forced vital capacity</measure>
    <time_frame>Analysis period: From day 1 in core study (Enrollment) to end-of-treatment (EOT) in the extension study, i.e. for up to 354 weeks</time_frame>
    <description>Determination of treatment-emergent decrease from baseline in FEV1 and FVC (absolute and % of predicted)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute change from baseline to end-of-study (EOS) versus change from baseline to end-of-treatment (EOT) in forced expiratory volume and forced vital capacity</measure>
    <time_frame>Analysis period: From day 1 in core study (Enrollment) to end-of-treatment (EOT) in the extension study, i.e. for up to 354 weeks</time_frame>
    <description>Absolute change from baseline to end-of-study (EOS) versus change from baseline to end-of-treatment (EOT) in FEV1 and FVC (absolute and % of predicted)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Ponesimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg administered orally once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ponesimod</intervention_name>
    <description>Ponesimod; Film-coated tablet; Oral use. From Day 1 to Day 14, ponesimod is gradually up-titrated until a maintenance dose of 20 mg is reached from Day 15</description>
    <arm_group_label>Ponesimod</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent

          2. Subjects with MS having completed the double-blind treatment in the core study as
             scheduled

          3. Compliance with teriflunomide elimination procedure

          4. Women of childbearing potential (WOCBP) must have a negative pre-treatment urine
             pregnancy test, must agree to undertake 4-weekly urine pregnancy tests, and must have
             been using reliable methods of contraception. Fertile male subjects participating in
             the study must agree to use a condom.

        Exclusion Criteria:

          1. Any of the following cardiovascular conditions on Day 1 pre-dose:

               1. Resting heart rate (HR) &lt; 50 bpm;

               2. Presence of second degree atrioventricular (AV) block or third degree AV block or
                  a QTcF interval &gt; 470 ms (females), &gt; 450 ms (males);

          2. Any of the following alerts from central laboratory at Visit 14 of the core study
             (EOT) which was confirmed as an alert at repeated testing or not repeated prior to FU1
             of the core study:

               1. Lymphocyte count: &lt; 0.2 x 109/L;

               2. Neutrophil count &lt;1.0 Ã— 109/L;

               3. Platelet count &lt; 50 Ã— 109/L;

               4. Creatinine clearance &lt; 30 mL/min

          3. At Visit 14 of the core study (EOT) &gt;30% decrease from core study baseline FEV1 and/or
             FVC;

          4. Clinically significant, persistent respiratory AEs (e.g., dyspnea) not resolved prior
             to first dosing in the extension study.

          5. Macular edema at any time between Visit 1 (Screening) in the core study and Day 1 of
             the extension study.

          6. Presence of the following at core study Visit 14 (EOT, Week 108), FU1, or abbreviated
             visit FU2, or on Day 1 of the extension study pre-dose:

               1. Suspected opportunistic infection of the CNS or any other infection which, in the
                  opinion of the investigator, contraindicates re-start of the study drug;

               2. Stevens-Johnson syndrome or toxic epidermal necrolysis or drug reaction with
                  eosinophilia and systemic symptoms.

          7. Need for and intention to administer forbidden study treatment-concomitant therapy

          8. Women who are pregnant or lactating.

          9. Male subjects wishing to parent a child;

         10. Treatment with any MS Disease Modifying Therapies;

         11. Any other clinically relevant medical or surgical condition, which, in the opinion of
             the investigator, would put the subject at risk by participating in the study;

         12. Subjects unlikely to comply with the extension study protocol based on investigator
             best judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tatiana Scherz, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Actelion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Research Center of Southern California, LLC</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida, Neurology Department</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephson Wallack Munshower Neurology, PC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh Neurology Associates - Dept of Neurology</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohiohealth Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GRODNO REGIONAL CLIN HOSP (Grodno)</name>
      <address>
        <city>Grodno</city>
        <zip>230017</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MINSK CITY HOSPITAL 5 NEUROLOGY (Minsk)</name>
      <address>
        <city>Minsk</city>
        <zip>220026</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practical Center of Neurology and Neurosurgery</name>
      <address>
        <city>Minsk</city>
        <zip>220114</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VITEBSK REGIONAL DIAGNOSTIC CENTER (Vitebsk)</name>
      <address>
        <city>Vitebsk</city>
        <zip>210023</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VITEBSK REGIONAL (Vitebsk)</name>
      <address>
        <city>Vitebsk</city>
        <zip>210037</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acibadem City Clinic Tokuda Hospital Ead</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty Hosp St Anna Brno Ms Ctr</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp Jihlava Neurol</name>
      <address>
        <city>Jihlava</city>
        <zip>586 33</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FACULTY HOSP OSTRAVA MS CTR (Ostrava-Poruba)</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOSP PARDUBICE MS CENTRUM (Pardubice)</name>
      <address>
        <city>Pardubice</city>
        <zip>532 03</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gen Faculty Hosp Prague Ms Ctr</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FACULT HOSP MOTOL, MS CENTRUM (Praha 5)</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOSP TEPLICE MS CTR (Teplice)</name>
      <address>
        <city>Teplice</city>
        <zip>415 29</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P. SARAJISHVILI INS NEUROLOG (Tbilisi)</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD AVERSI CLIN (Tbilisi)</name>
      <address>
        <city>Tbilisi</city>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.KHECHINASHVILI UNIV HOSP (Tbilisi)</name>
      <address>
        <city>Tbilisi</city>
        <zip>0179</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CURATIO, JSC (Tbilisi)</name>
      <address>
        <city>Tbilisi</city>
        <zip>0194</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AFL ARZNEIMITTELFORSCHUNG LEIPZIG GMBH (Leipzig)</name>
      <address>
        <city>Leipzig</city>
        <zip>04107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VALEOMED EGÃ‰SZSÃ‰GKÃ–ZPONT (Esztergom)</name>
      <address>
        <city>Esztergom</city>
        <zip>2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center - Neurology Department</name>
      <address>
        <city>Ashkelon</city>
        <zip>7830604</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Med Center Neuro Dep</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Department, Ziv Medical Center</name>
      <address>
        <city>Sefad</city>
        <zip>1304300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LATVIAN MARITIME MEDICINE CENTER RIGA (Riga)</name>
      <address>
        <city>Riga</city>
        <zip>1015</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL NEUROLOGY (RÄ«ga)</name>
      <address>
        <city>RÄ«ga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Bydgoszcz Priv</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-795</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology GdaÅ„sk Priv (GdaÅ„sk)</name>
      <address>
        <city>GdaÅ„sk</city>
        <zip>80-803</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KMK-Clinical Sp. z o.o. NZOZ Rawa-Med</name>
      <address>
        <city>Katowice</city>
        <zip>40-571</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEURO-MEDIC Janusz Zbrojkiewicz Poradnia Wielospecjalistyczna</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEUROLOGY KSAWERÃ“W PRIV (KsawerÃ³w)</name>
      <address>
        <city>KsawerÃ³w</city>
        <zip>95-054</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEUROLOGY LUBLIN PRIV2 (Lublin)</name>
      <address>
        <city>Lublin</city>
        <zip>20-015</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology PoznaÅ„ Priv2</name>
      <address>
        <city>PoznaÅ„</city>
        <zip>60-848</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEUROLOGY POZNAÅƒ PRIV (PoznaÅ„)</name>
      <address>
        <city>PoznaÅ„</city>
        <zip>61-853</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology WrocÅ‚aw Priv2</name>
      <address>
        <city>WrocÅ‚aw</city>
        <zip>51-685</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>COUNTY CLIN EMERGENCY HOSP - II NEUROLOGY (Timisoara)</name>
      <address>
        <city>Timisoara</city>
        <zip>300723</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BARNAUL TERRITORIAL CLIN HOSP (Barnaul, Altai Krai)</name>
      <address>
        <city>Barnaul, Altai Krai</city>
        <zip>656024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Belgorod Reg Hosp</name>
      <address>
        <city>Belgorod</city>
        <zip>308007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BRYANSK REG HOSP 1 (Bryansk)</name>
      <address>
        <city>Bryansk</city>
        <zip>241033</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SVERDLOVSK REG CLIN HOSP #1 (Ekaterinburg)</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Res Med Complex &quot;Your Health&quot; Ltd.</name>
      <address>
        <city>Kazan</city>
        <zip>420097</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FEDERAL SIBERIAN SCIENTIFIC CLINICAL CENTER (Krasnoyarsk)</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660037</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kursk Reg Clin Hosp</name>
      <address>
        <city>Kursk</city>
        <zip>305007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PIROGOV CITY CLIN HOSP 1 (Moscow)</name>
      <address>
        <city>Moscow</city>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MOSCOW CITY CLINICAL HOSPITAL 24 (Moscow)</name>
      <address>
        <city>Moscow</city>
        <zip>127015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOSPITAL #2 N.A. SEMASHKO OF THE RZHD, NEUROLOGY (Moscow)</name>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital # 3</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603155</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIZHNY NOVGOROD CITY HOSP 33 (Nizhny Novgorod)</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siberian District Medical Center</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FEDERAL CENTER OF PHYSICO-CHEMICAL MEDICINE (Odintsovo)</name>
      <address>
        <city>Odintsovo</city>
        <zip>143000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PERM STATE MED ACAD VAGNER (Perm)</name>
      <address>
        <city>Perm</city>
        <zip>614990</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital # 2</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357538</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samara Regional Clinical Hospital n.a. Seredavin</name>
      <address>
        <city>Samara</city>
        <zip>443095</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMOLENSK STATE MED UNIVERSITY (Smolensk)</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ST. PETERSBURG PAVLOV STATE MEDICAL UNIVERSITY (St. Petersburg)</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Human Brain Ras</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197376</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Multi-Specialty Hospital # 2</name>
      <address>
        <city>St.Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #31, Center For Multiple Sclerosis</name>
      <address>
        <city>St.Petersburg</city>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Petersburg City Hospital #40</name>
      <address>
        <city>St.Petersburg</city>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SIBERIAN STATE MEDICAL UNIVERSITY, NEUROLOGY (Tomsk)</name>
      <address>
        <city>Tomsk</city>
        <zip>634050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TVER REG CLIN CTR RECONSTRUCTIVE MED &amp; REHAB (Tver)</name>
      <address>
        <city>Tver</city>
        <zip>170026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yaroslavl Clinical Hospital #8</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CLIN CTR KRAGUJEVAC - NEUROLOGY (Kragujevac)</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp Vall DÂ´Hebron Dpt Neurology</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOSPITAL REGIONAL UNIVERSITARIO DE MALAGA (Malaga)</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital, Ms Center</name>
      <address>
        <city>GÃ¶teborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CENTRUM FOR NEUROLOGI (Stockholm)</name>
      <address>
        <city>Stockholm</city>
        <zip>113 65</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chernihiv City Hospital #4, Department of Neurology</name>
      <address>
        <city>Chernihiv</city>
        <zip>14001</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pub Treat Proph Inst, Chernihiv Reg Hosp</name>
      <address>
        <city>Chernihiv</city>
        <zip>14029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk Regional Clinical Hospital</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kharkiv Railway Clin Hosp #1</name>
      <address>
        <city>Kharkiv</city>
        <zip>61103</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kharkiv Postgrad Academy, Dept of Neurology #1 At Hosp #7</name>
      <address>
        <city>Kharkiv</city>
        <zip>61176</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NAT RES CTR FOR RAD MED PSYCHONEUROLOG RAD DEPT (Kyiv)</name>
      <address>
        <city>Kyiv</city>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public City Clin Hosp 5, Neurolog Dept (Lviv)</name>
      <address>
        <city>Lviv</city>
        <zip>79000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv Regional Clinical Hospital, Department of Neurology</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center For Reconstructive and Restorative Medicine (University Clinic) of Odesa National Medical University</name>
      <address>
        <city>Odesa</city>
        <zip>65009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poltava M.V. Sklifosovskyi Reg Clin Hosp, Neurolg Dept</name>
      <address>
        <city>Poltava</city>
        <zip>36011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ternopil Regional Public Clinical Psychoneurology Hospital, Department of Neurology</name>
      <address>
        <city>Ternopil</city>
        <zip>46027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnytsia O.I. Yushchenko Regional Psychoneurology Hospital, Neurology Department #3</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>O.F. HERBACHEVSKYI REG CLIN HOSP NEUROLOG DEPT (Zhytomyr)</name>
      <address>
        <city>Zhytomyr</city>
        <zip>10008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ROYAL PRESTON HOSPITAL (Lancashire)</name>
      <address>
        <city>Lancashire</city>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2017</study_first_submitted>
  <study_first_submitted_qc>July 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2017</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

